FI58433C - Foerfarande foer framstaellning av ett oftalmiskt preparat - Google Patents
Foerfarande foer framstaellning av ett oftalmiskt preparat Download PDFInfo
- Publication number
- FI58433C FI58433C FI3522/74A FI352274A FI58433C FI 58433 C FI58433 C FI 58433C FI 3522/74 A FI3522/74 A FI 3522/74A FI 352274 A FI352274 A FI 352274A FI 58433 C FI58433 C FI 58433C
- Authority
- FI
- Finland
- Prior art keywords
- eye
- pilocarpine
- inserts
- ophthalmic
- hydroxypropylcellulose
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 20
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 17
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 17
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims description 22
- 229960001416 pilocarpine Drugs 0.000 claims description 22
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 12
- 239000004014 plasticizer Substances 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 7
- 238000001125 extrusion Methods 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000000465 moulding Methods 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003604 miotic agent Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 17
- 238000011282 treatment Methods 0.000 abstract description 13
- 230000002035 prolonged effect Effects 0.000 abstract description 3
- 239000012876 carrier material Substances 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 description 21
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 235000010443 alginic acid Nutrition 0.000 description 7
- 229920000615 alginic acid Polymers 0.000 description 7
- 230000003547 miosis Effects 0.000 description 7
- -1 alginic acid salt Chemical class 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 208000022873 Ocular disease Diseases 0.000 description 4
- 239000000783 alginic acid Substances 0.000 description 4
- 229960001126 alginic acid Drugs 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 239000010409 thin film Substances 0.000 description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- GIKNHHRFLCDOEU-UHFFFAOYSA-N 4-(2-aminopropyl)phenol Chemical compound CC(N)CC1=CC=C(O)C=C1 GIKNHHRFLCDOEU-UHFFFAOYSA-N 0.000 description 2
- ZCECPEINCZVBPT-IWXKTIJTSA-N 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;(3s,4r)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 ZCECPEINCZVBPT-IWXKTIJTSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- NHTGQOXRZFUGJX-UHFFFAOYSA-N chlorquinox Chemical compound N1=CC=NC2=C(Cl)C(Cl)=C(Cl)C(Cl)=C21 NHTGQOXRZFUGJX-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 235000012438 extruded product Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 239000004416 thermosoftening plastic Substances 0.000 description 2
- WJRPDGADPABWOY-WPRPVWTQSA-N (2s,3r)-2-ethyl-3-(hydroxymethyl)-4-(3-methylimidazol-4-yl)butanoic acid Chemical class CC[C@H](C(O)=O)[C@H](CO)CC1=CN=CN1C WJRPDGADPABWOY-WPRPVWTQSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- LCZVSXRMYJUNFX-UHFFFAOYSA-N 2-[2-(2-hydroxypropoxy)propoxy]propan-1-ol Chemical compound CC(O)COC(C)COC(C)CO LCZVSXRMYJUNFX-UHFFFAOYSA-N 0.000 description 1
- YKFROQCFVXOUPW-UHFFFAOYSA-N 4-(methylthio) aniline Chemical compound CSC1=CC=C(N)C=C1 YKFROQCFVXOUPW-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 208000016134 Conjunctival disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- ZTVIKZXZYLEVOL-MCOXGKPRSA-N Homatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-MCOXGKPRSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940055075 anticholinesterase parasympathomimetics Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 208000001936 exophthalmos Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960000857 homatropine Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229950005360 hydroxyamfetamine Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 229960001963 pilocarpine nitrate Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Ceramic Products (AREA)
- Hydrogenated Pyridines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI801272A FI801272A7 (fi) | 1973-12-17 | 1980-04-21 | Saett att plasticera ett fast medicinskt preparat |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42542673A | 1973-12-17 | 1973-12-17 | |
| US42542673 | 1973-12-17 | ||
| US51932374A | 1974-10-31 | 1974-10-31 | |
| US51932374 | 1974-10-31 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI352274A7 FI352274A7 (enrdf_load_stackoverflow) | 1975-06-18 |
| FI58433B FI58433B (fi) | 1980-10-31 |
| FI58433C true FI58433C (fi) | 1981-02-10 |
Family
ID=27026681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI3522/74A FI58433C (fi) | 1973-12-17 | 1974-12-05 | Foerfarande foer framstaellning av ett oftalmiskt preparat |
Country Status (25)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4076942A (en) * | 1975-10-01 | 1978-02-28 | Merck & Co., Inc. | Crystalline dipilocarpinium pamoate |
| US4255415A (en) * | 1978-11-22 | 1981-03-10 | Schering Corporation | Polyvinyl alcohol ophthalmic gel |
| JPS5758615A (en) * | 1980-09-26 | 1982-04-08 | Nippon Soda Co Ltd | Film agnent and its preparation |
| NZ200429A (en) * | 1981-04-30 | 1984-10-19 | Smith & Nephew Ass | Applicator for placing pharmaceutically active agent in contact with moist surface,e.g.,eye |
| JPS59501159A (ja) * | 1982-06-24 | 1984-07-05 | スミス、ロバ−ト・アラン | 薬用ゲル組成物 |
| CH667001A5 (de) * | 1985-09-03 | 1988-09-15 | Hugo Degen | Untermatratze. |
| US5036046A (en) * | 1988-10-12 | 1991-07-30 | Eye Research Institute Of Retina Foundation, Inc. | Method for enhancing healing of corneal endothelial wounds |
| DE19508029C2 (de) * | 1995-03-07 | 1997-10-09 | Richard Prof Dr Sueverkruep | Darreichungsform zur äußerlichen Applikation von ophthalmischen Arzneistoffen und Verfahren zur Herstellung derselben |
| JP5081413B2 (ja) * | 2005-07-29 | 2012-11-28 | 参天製薬株式会社 | 固形組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム |
| ES2603057T3 (es) * | 2009-10-30 | 2017-02-23 | Aton Pharma, Inc. | Dispositivos de administración ocular de fármacos |
| WO2023214027A1 (en) | 2022-05-06 | 2023-11-09 | Eyed Pharma | Insert for the treatment of dry eyes |
| BE1030504B1 (fr) | 2022-05-06 | 2023-12-04 | Eyed Pharma | Insert composite pour le traitement de la sécheresse oculaire |
| BE1030503B1 (fr) | 2022-05-06 | 2023-12-04 | Eyed Pharma | Insert pour le traitement de la sécheresse oculaire |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3875300A (en) * | 1972-12-18 | 1975-04-01 | Ortho Pharma Corp | Composition for sustained release of a medicament and method of using same |
-
1974
- 1974-12-04 DK DK629774AA patent/DK137946B/da not_active IP Right Cessation
- 1974-12-05 NO NO744394A patent/NO140489C/no unknown
- 1974-12-05 FI FI3522/74A patent/FI58433C/fi active
- 1974-12-05 NL NL7415883.A patent/NL167326C/xx not_active IP Right Cessation
- 1974-12-05 SE SE7415248A patent/SE408014B/xx unknown
- 1974-12-10 AU AU76235/74A patent/AU509331B2/en not_active Expired
- 1974-12-10 CA CA215,644A patent/CA1063022A/en not_active Expired
- 1974-12-10 IE IE2537/74A patent/IE40466B1/xx unknown
- 1974-12-10 IL IL46209A patent/IL46209A/xx unknown
- 1974-12-11 EG EG547/74A patent/EG11698A/xx active
- 1974-12-12 GB GB7147/77A patent/GB1485150A/en not_active Expired
- 1974-12-12 GB GB53868/74A patent/GB1485149A/en not_active Expired
- 1974-12-12 ES ES432866A patent/ES432866A1/es not_active Expired
- 1974-12-13 FR FR7441202A patent/FR2254350B1/fr not_active Expired
- 1974-12-13 CH CH1663174A patent/CH611797A5/xx not_active IP Right Cessation
- 1974-12-13 HU HU74ME00001814A patent/HU171803B/hu unknown
- 1974-12-13 CH CH217078A patent/CH609864A5/xx not_active IP Right Cessation
- 1974-12-13 PH PH16625A patent/PH10938A/en unknown
- 1974-12-13 AT AT996174A patent/AT333945B/de not_active IP Right Cessation
- 1974-12-14 DD DD188554A patent/DD121643A5/xx unknown
- 1974-12-14 DD DD183050A patent/DD117349A5/xx unknown
- 1974-12-16 RO RO7400084550A patent/RO63070A/ro unknown
- 1974-12-16 IT IT54580/74A patent/IT1056094B/it active
- 1974-12-16 DE DE2462081A patent/DE2462081C3/de not_active Expired
- 1974-12-16 LU LU71490A patent/LU71490A1/xx unknown
- 1974-12-16 DE DE2459391A patent/DE2459391C3/de not_active Expired
- 1974-12-17 JP JP14412274A patent/JPS5636173B2/ja not_active Expired
-
1976
- 1976-08-26 ES ES451015A patent/ES451015A1/es not_active Expired
-
1977
- 1977-02-17 PH PH19458A patent/PH17250A/en unknown
-
1980
- 1980-05-23 KE KE3049A patent/KE3049A/xx unknown
- 1980-06-05 HK HK308/80A patent/HK30880A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4179497A (en) | Solid state ophthalmic medication | |
| FI58433C (fi) | Foerfarande foer framstaellning av ett oftalmiskt preparat | |
| DE69430796T2 (de) | Thalidomid zur hemmung der angiogenese | |
| US6495157B1 (en) | Intravaginal clindamycin ovule composition | |
| US20200069583A1 (en) | In situ phase change gel sustained-release system for small molecule drug and preparation method thereof | |
| KR20090091769A (ko) | 안과용 약물의 전달에 유용한 젤 | |
| DE3310079A1 (de) | Topische ophthalmische arzneimittel | |
| US20120309823A1 (en) | Percutaneous absorption preparations | |
| JPH04259467A (ja) | ヒト及び動物医薬用材料 | |
| Deshpande et al. | Sustained release ophthalmic formulations of pilocarpine | |
| DE69119217T2 (de) | Zusammensetzungen zur kontrollierten freigabe | |
| CN101401791A (zh) | 噻吗洛尔脂质体及其制备方法 | |
| KR100658436B1 (ko) | 아데노실코발라민 함유 피부질환 치료용 외용제 조성물 | |
| CN113679658A (zh) | 用于皮肤止痒抗过敏治疗的可溶性微针贴片及其制备方法 | |
| KR100229842B1 (ko) | 지속적 방출형 안과용 제제 | |
| Khushbuben | Development and Evaluation of in Situ Gelling System for the Treatment of Periodontitis | |
| EP0077261B1 (en) | Biosoluble ocular insert | |
| KR100623788B1 (ko) | 호르몬 조성물 및 이의 용도 | |
| EP0784975A1 (en) | Use of acetylsalicylic acid in the manufacture of a drug for the treatment of skin injuries | |
| JP2000506833A (ja) | 斑水腫の治療 | |
| CN104338147B (zh) | 一种用于缓控释给药的软膏组合基质 | |
| US8663678B2 (en) | Solid dosage form for the ocular administration of an active principle, a soluble, solid ophthalmic insert and the production method thereof | |
| Thakur et al. | Development and optimization of controlled release bioerodable anti infective ophthalmic insert | |
| EP0108661A1 (en) | Stabilized hydroxypropyl cellulose ophthalmic inserts and process to sterilize the same | |
| Banu et al. | Ocular Drug Delivery System: A Novel Approach |